A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder
This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder. All participants received a starting dose of brexpiprazole.
While the availability of atypical antipsychotics had increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive episodes of bipolar I disorder. Brexpiprazole's specific receptor activity profile likely correlates with its established efficacy in schizophrenia and major depressive disorder, and may prove to be an effective target for the treatment of acute mania of bipolar I disorder.
Inclusion Criteria (rollover participants from 331-201-00080 & 331-201-00081 trials)
Exclusion Criteria (rollover participants from 331-201-00080 & 331-201-00081 trials)
Burgas, 8000, Bulgaria
Kardzhali, 6600, Bulgaria
Novi Iskar, 1282, Bulgaria
Plovdiv, 4002, Bulgaria
Rousse, 7003, Bulgaria
Sofia, 1431, Bulgaria
Targovishte, 7700, Bulgaria
Veliko Tarnovo, 5000, Bulgaria
Lviv, 79021, Ukraine